The Effect of Hydroxyurea on Hemoglobin F in Patients With Myeloproliferative Syndromes

Fetal hemoglobin (Hb F) may increase in patients receiving chemotherapeutic drugs, a result of potential use in patients with symptomatic hemoglobinopathies. We examined Hb F in 13 patients with myeloproliferative disease (six polycythemia vera, five polycythemia vera with myeloid metaplasia, one ag...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1985-08, Vol.66 (2), p.373-379
Main Authors: Alter, Blanche P., Gilbert, Harriet S.
Format: Article
Language:English
Subjects:
Adult
Aged
Applied sciences
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Erythrocyte Indices
Exact sciences and technology
Female
Fetal Hemoglobin - analysis
Humans
Hydroxyurea - therapeutic use
Male
Medical sciences
Middle Aged
Myeloproliferative Disorders - blood
Myeloproliferative Disorders - drug therapy
Other techniques and industries
Pharmacology. Drug treatments
Polycythemia Vera - drug therapy
Primary Myelofibrosis - drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fetal hemoglobin (Hb F) may increase in patients receiving chemotherapeutic drugs, a result of potential use in patients with symptomatic hemoglobinopathies. We examined Hb F in 13 patients with myeloproliferative disease (six polycythemia vera, five polycythemia vera with myeloid metaplasia, one agnogenic myeloid metaplasia, and one chronic myelogenous leukemia) who were treated with hydroxyurea. Four patients showed an increase in Hb F from 8% while on hydroxyurea, and a decline to
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V66.2.373.373